Ambit Biosciences and Astellas Pharma Inc. Announce Upcoming Presentation of AC220 Data at the 16th Annual Congress of the European Hematology Association

SAN DIEGO & TOKYO--(BUSINESS WIRE)--Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that the first presentation of interim data from a global multi-center Phase 2 study evaluating the investigational drug AC220, a potent and selective FLT3 inhibitor. The data will be presented in an oral session at the upcoming European Hematology Association (EHA) meeting in London. The abstract (#1019) can be accessed at the EHA Congress website at http://eha.eurocongres.com/16th/. Details of the presentation are as follows